Kathryn Coyle, Prashant Kumar Singh, Ravi Kaushik, Rumana Huque, Zohaib Khan, Ravi Mehrotra, Kamran Siddiqi, Subhash Pokhrel
{"title":"孟加拉国、印度和巴基斯坦使用无烟烟草的终生健康和经济负担:ASTRAMOD 的结果。","authors":"Kathryn Coyle, Prashant Kumar Singh, Ravi Kaushik, Rumana Huque, Zohaib Khan, Ravi Mehrotra, Kamran Siddiqi, Subhash Pokhrel","doi":"10.1093/ntr/ntae067","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Under the current policy landscapes, the lifetime health and economic burden of smokeless tobacco (ST) products, consumed by over 297 million ST users in South Asia, is unknown. The aim of this study was to estimate the lifetime health effects and costs attributable to current and future ST use in Bangladesh, India, and Pakistan where the majority of ST users live.</p><p><strong>Aims and methods: </strong>We developed a Markov-based state-transition model (ASTRAMOD) to predict the lifetime costs of treatment of four diseases (oral, pharyngeal, esophageal cancers, and stroke) and disability-adjusted life years (DALYs), attributable to the current and future use of ST under existing ST policy scenario. Country-specific Global Adult Tobacco Surveys, life tables, and meta-analyses of South Asian and South East Asian studies were used to populate the model. A probabilistic sensitivity analysis evaluated the uncertainty in model predictions.</p><p><strong>Results: </strong>If there were no change in the current ST policies, the lifetime ST-attributable treatment costs would be over US$19 billion in India, over US$1.5 billion in Bangladesh, and over US$3 billion in Pakistan. For all countries, the attributable costs are higher for younger cohorts with costs declining with increasing age for those over 50. The model predicted that a typical 15-year-old male adoloscent would gain 0.07-0.18 life years, avert 0.07-0.19 DALYs, and generate a cost-savings of US$7-21 on healthcare spending if ST policies were changed to eliminate ST use.</p><p><strong>Conclusions: </strong>Policy interventions aimed at decreasing the uptake of ST and increasing quitting success have the potential to substantially decrease the economic and health burden of ST.</p><p><strong>Implications: </strong>This study provides the most comprehensive estimates of the lifetime health and economic burden of ST by 5-year age and sex cohorts. This is also the first study that highlights the scale of health and economic burden of ST in Bangladesh, India, and Pakistan if there were no changes in the current ST policies. Policymakers and practitioners can use the reported data to justify their decisions to improve current ST policies and practices in their country. Researchers can use the ASTRAMOD methodology to estimate the impact of future ST policy changes.</p>","PeriodicalId":19241,"journal":{"name":"Nicotine & Tobacco Research","volume":" ","pages":"684-692"},"PeriodicalIF":3.0000,"publicationDate":"2025-03-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11931212/pdf/","citationCount":"0","resultStr":"{\"title\":\"The Lifetime Health and Economic Burden of Smokeless Tobacco use in Bangladesh, India, and Pakistan: Results From ASTRAMOD.\",\"authors\":\"Kathryn Coyle, Prashant Kumar Singh, Ravi Kaushik, Rumana Huque, Zohaib Khan, Ravi Mehrotra, Kamran Siddiqi, Subhash Pokhrel\",\"doi\":\"10.1093/ntr/ntae067\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Introduction: </strong>Under the current policy landscapes, the lifetime health and economic burden of smokeless tobacco (ST) products, consumed by over 297 million ST users in South Asia, is unknown. The aim of this study was to estimate the lifetime health effects and costs attributable to current and future ST use in Bangladesh, India, and Pakistan where the majority of ST users live.</p><p><strong>Aims and methods: </strong>We developed a Markov-based state-transition model (ASTRAMOD) to predict the lifetime costs of treatment of four diseases (oral, pharyngeal, esophageal cancers, and stroke) and disability-adjusted life years (DALYs), attributable to the current and future use of ST under existing ST policy scenario. Country-specific Global Adult Tobacco Surveys, life tables, and meta-analyses of South Asian and South East Asian studies were used to populate the model. A probabilistic sensitivity analysis evaluated the uncertainty in model predictions.</p><p><strong>Results: </strong>If there were no change in the current ST policies, the lifetime ST-attributable treatment costs would be over US$19 billion in India, over US$1.5 billion in Bangladesh, and over US$3 billion in Pakistan. For all countries, the attributable costs are higher for younger cohorts with costs declining with increasing age for those over 50. The model predicted that a typical 15-year-old male adoloscent would gain 0.07-0.18 life years, avert 0.07-0.19 DALYs, and generate a cost-savings of US$7-21 on healthcare spending if ST policies were changed to eliminate ST use.</p><p><strong>Conclusions: </strong>Policy interventions aimed at decreasing the uptake of ST and increasing quitting success have the potential to substantially decrease the economic and health burden of ST.</p><p><strong>Implications: </strong>This study provides the most comprehensive estimates of the lifetime health and economic burden of ST by 5-year age and sex cohorts. This is also the first study that highlights the scale of health and economic burden of ST in Bangladesh, India, and Pakistan if there were no changes in the current ST policies. Policymakers and practitioners can use the reported data to justify their decisions to improve current ST policies and practices in their country. Researchers can use the ASTRAMOD methodology to estimate the impact of future ST policy changes.</p>\",\"PeriodicalId\":19241,\"journal\":{\"name\":\"Nicotine & Tobacco Research\",\"volume\":\" \",\"pages\":\"684-692\"},\"PeriodicalIF\":3.0000,\"publicationDate\":\"2025-03-24\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11931212/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Nicotine & Tobacco Research\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1093/ntr/ntae067\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nicotine & Tobacco Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/ntr/ntae067","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH","Score":null,"Total":0}
引用次数: 0
摘要
导言:在目前的政策环境下,南亚超过 2.97 亿无烟烟草(ST)使用者终生使用无烟烟草产品所带来的健康和经济负担尚不清楚。本研究旨在估算孟加拉国、印度和巴基斯坦当前和未来使用无烟烟草产品对健康造成的影响和产生的成本,这些国家是大多数无烟烟草使用者的居住地:我们开发了一个基于马尔可夫的状态转换模型(ASTRAMOD),以预测在现有 ST 政策情景下,因当前和未来使用 ST 而导致的四种疾病(口腔癌、咽癌、食道癌和中风)的终生治疗成本和残疾调整生命年(DALYs)。该模型采用了针对具体国家的全球成人烟草调查、生命表以及对南亚和东南亚研究的荟萃分析。概率敏感性分析评估了模型预测的不确定性:结果:如果不改变现行的 ST 政策,印度的终生 ST 归因治疗成本将超过 190 亿美元,孟加拉国将超过 15 亿美元,巴基斯坦将超过 30 亿美元。在所有国家中,年轻群体的可归因成本较高,而 50 岁以上人群的可归因成本则随着年龄的增长而下降。该模型预测,如果改变 ST 政策以消除 ST 的使用,典型的 15 岁男性 adoloscent 将获得 0.07-0.18 年的寿命,避免 0.07-0.19 个残疾调整寿命年,并在医疗保健支出方面节省 7-21 美元的成本:结论:旨在减少使用 ST 和提高戒烟成功率的政策干预措施有可能大幅降低 ST 带来的经济和健康负担:本研究提供了按 5 年年龄和性别组群划分的 ST 终生健康和经济负担的最全面估算。这也是第一项研究,它强调了如果不改变现行的 ST 政策,孟加拉国、印度和巴基斯坦的 ST 健康和经济负担的规模。政策制定者和从业人员可以利用报告中的数据来证明他们改进本国现行 ST 政策和实践的决定是正确的。研究人员可以使用 ASTRAMOD 方法估算未来 ST 政策变化的影响。
The Lifetime Health and Economic Burden of Smokeless Tobacco use in Bangladesh, India, and Pakistan: Results From ASTRAMOD.
Introduction: Under the current policy landscapes, the lifetime health and economic burden of smokeless tobacco (ST) products, consumed by over 297 million ST users in South Asia, is unknown. The aim of this study was to estimate the lifetime health effects and costs attributable to current and future ST use in Bangladesh, India, and Pakistan where the majority of ST users live.
Aims and methods: We developed a Markov-based state-transition model (ASTRAMOD) to predict the lifetime costs of treatment of four diseases (oral, pharyngeal, esophageal cancers, and stroke) and disability-adjusted life years (DALYs), attributable to the current and future use of ST under existing ST policy scenario. Country-specific Global Adult Tobacco Surveys, life tables, and meta-analyses of South Asian and South East Asian studies were used to populate the model. A probabilistic sensitivity analysis evaluated the uncertainty in model predictions.
Results: If there were no change in the current ST policies, the lifetime ST-attributable treatment costs would be over US$19 billion in India, over US$1.5 billion in Bangladesh, and over US$3 billion in Pakistan. For all countries, the attributable costs are higher for younger cohorts with costs declining with increasing age for those over 50. The model predicted that a typical 15-year-old male adoloscent would gain 0.07-0.18 life years, avert 0.07-0.19 DALYs, and generate a cost-savings of US$7-21 on healthcare spending if ST policies were changed to eliminate ST use.
Conclusions: Policy interventions aimed at decreasing the uptake of ST and increasing quitting success have the potential to substantially decrease the economic and health burden of ST.
Implications: This study provides the most comprehensive estimates of the lifetime health and economic burden of ST by 5-year age and sex cohorts. This is also the first study that highlights the scale of health and economic burden of ST in Bangladesh, India, and Pakistan if there were no changes in the current ST policies. Policymakers and practitioners can use the reported data to justify their decisions to improve current ST policies and practices in their country. Researchers can use the ASTRAMOD methodology to estimate the impact of future ST policy changes.
期刊介绍:
Nicotine & Tobacco Research is one of the world''s few peer-reviewed journals devoted exclusively to the study of nicotine and tobacco.
It aims to provide a forum for empirical findings, critical reviews, and conceptual papers on the many aspects of nicotine and tobacco, including research from the biobehavioral, neurobiological, molecular biologic, epidemiological, prevention, and treatment arenas.
Along with manuscripts from each of the areas mentioned above, the editors encourage submissions that are integrative in nature and that cross traditional disciplinary boundaries.
The journal is sponsored by the Society for Research on Nicotine and Tobacco (SRNT). It publishes twelve times a year.